Hemispherx Biopharma (HEB) Reports Q1 Loss of $0.02/Share

Hemispherx Biopharma (NYSE: HEB) reported Q1 EPS of ($0.02), versus ($0.02) reported last year.

Cash, cash equivalents and marketable securities were approximately $17,005,000 at March 31, 2015 as compared to $16,108,000 as of December 31, 2014.

For earnings history and earnings-related data on Hemispherx Biopharma (HEB) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Boost Run, Inc. (BRUN) Reports Q2 Revenue of $31.1M